Publications To Date


    Filter Publications

    PAGE 1 OF 9 | DISPLAYING 1 - 15 OF 134 RESULTS

    Watts A.M. et. al., Distinct Gene Expression Patterns between Nasal Mucosal Cells and Blood Collected from Allergic Rhinitis Sufferers., 10.1159/000489609, Int Arch Allergy Immunol. , Dec 18, 2018

    Bommareddy P.K. et. al., MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation, 10.1126/scitranslmed.aau0417 , Science, Dec 12, 2018

    Chon H.J. et. al., Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade., 10.1158/1078-0432.CCR-18-1932, Clin. Can. Res., Dec 11, 2018

    Grabosch S. et. al., Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles,, Oncogene, Dec 05, 2018

    Hillen L.M. et. al., Molecular profiling of Spitz nevi identified by digital RNA counting., 10.1097/CMR.0000000000000495., Melanoma Res., Dec 01, 2018

    Christmas B.J. et. al., Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs, 10.1158/2326-6066.CIR-18-0070, Can. Immunol. Res., Dec 01, 2018

    Gomes B. et. al., Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy, 10.1158/1535-7163.MCT-17-1104, Mol. Can. Ther., Dec 01, 2018

    Tanaka H. et. al., Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer, 10.1158/1535-7163.MCT-17-1180, Mol. Can. Ther., Dec 01, 2018

    Fenerty K.E. et. al., Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition, 10.1186/s40425-018-0445-4, J. Immunother. Cancer, Nov 29, 2018

    Yu J.W. et. al., Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments, 10.1371/journal.pone.0206223, PLoS ONE, Nov 02, 2018

    Du W. et. al., Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, 10.1172/jci.insight.124184, JCI Insight, Nov 02, 2018

    Szekely B. et. al., Immunological differences between primary and metastatic breast cancer., doi: 10.1093/annonc/mdy399., Ann. Oncol., Nov 01, 2018

    Tan T.Z. et. al., Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer., 10.1002/path.5191, J. Pathol., Oct 30, 2018

    Grellety T. et. al., Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target., 10.1158/1078-0432.CCR-18-1469, Clin. Can. Res., Oct 23, 2018

    Dhage S. et. al., A genomic ruler to assess oncogenic transition between breast tumor and stroma, 10.1371/journal.pone.0205602, PLoS ONE, Oct 16, 2018